In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thermo Fisher Scientific Inc.

www.thermofisher.com

Latest From Thermo Fisher Scientific Inc.

Freeline Bags Alnylam's Heggie As CEO

Syncona-backed Freeline has nabbed an "accomplished commercial leader" in Theresa Heggie to lead the company as it prepares to take FLT180a, its gene therapy for hemophilia B, into Phase III.

Blood & Coagulation Disorders Gene Therapy

Civica Interested In Retired Or Withdrawn ANDAs

As a part of its strategy to develop its own ANDAs for essential medications, Civica has expressed interest in taking over existing ANDAs that are being retired or withdrawn by other generics manufacturers.

Strategy Generic Drugs

Leading Medtechs See Organic Growth Across A Market In Flux

In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.

Financing Outlook 2020

MTI Top 100: Leading Medtechs See Steady Organic Growth In A Market On The Cusp Of Change

The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings. 

International Commercial
See All

Company Information

UsernamePublicRestriction

Register